<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361088</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13971</org_study_id>
    <secondary_id>7032</secondary_id>
    <nct_id>NCT00361088</nct_id>
  </id_info>
  <brief_title>A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma</brief_title>
  <official_title>A Dose Escalation of Zarnestra (R115777) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Phase I, patients will receive a combination of PS-341 (Velcade) and R115777 (Zarnestra)&#xD;
      to determine the dose limiting toxicity (DLT). Once DLT is determined, patients in Phase II&#xD;
      will be receive the maximum tolerated dose (MTD) to complete 8 cycles of therapy. Treatment&#xD;
      will continue if there is evidence of continued response for 8 cycles. Patients will receive&#xD;
      follow up to include normal laboratory evaluations at least every 3 months and a skeletal&#xD;
      survey will be performed at least every 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase I, patients will receive intravenous PS-341 (Velcade) and 3 different dose levels of&#xD;
      oral R115777 (Zarnestra). Dose Limiting Toxicity (DLT) will be determined over a period of&#xD;
      one cycle and dose escalation to the next level will not occur until all patients projected&#xD;
      at each level complete one cycle of therapy. Once DLT is determined, patients in Phase I and&#xD;
      all patients enrolled for the phase II component will be treated at the maximum tolerated&#xD;
      dose (MTD) to complete 8 cycles of therapy. Treatment will continue beyond 8 cycles if there&#xD;
      is evidence of continued response. The study regimen will consist of two weeks of treatment&#xD;
      followed by one week off for a total cycle duration of three weeks. If disease stabilization&#xD;
      occurs (noted on 2 consecutive cycles) after the standard 8 cycles are given, treatment will&#xD;
      be discontinued.&#xD;
&#xD;
      Patients are to be monitored for adverse events throughout the treatment phases and for a&#xD;
      minimum of 30 days after their last dose of drugs. Follow up will include history and&#xD;
      physical exam with laboratory evaluation at least every 3 months. Laboratories will include&#xD;
      CMP, CBC, SPEP, UPEP, and quantitative immunoglobulins. A skeletal survey will be performed&#xD;
      at least every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Initial Principal Investigator left Moffitt&#xD;
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Average of 6 months</time_frame>
    <description>Determine the dose limiting toxicity at 3 weeks post treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Average of 6 months</time_frame>
    <description>Determine the maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rates</measure>
    <time_frame>Average of 6 months</time_frame>
    <description>Determine response rates after 8 cycles of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Average of 6 months</time_frame>
    <description>Determine toxicity profiles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Average of 12 months</time_frame>
    <description>Determine progression free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PS-341</intervention_name>
    <description>Phase I and II: 1.3mg/m2 iv days 1,4,8,11</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>bortezomib</other_name>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R11577</intervention_name>
    <description>Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.&#xD;
Phase II: Maximum Tolerated Dose (MTD)</description>
    <arm_group_label>Phase I</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Zarnestra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary written informed consent&#xD;
&#xD;
          -  Female subject is either post-menopausal/surgically sterilized or willing to use an&#xD;
             acceptable method of birth control for the duration of the study.&#xD;
&#xD;
          -  Male subject agrees to use an acceptable method for contraception for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  Diagnosis of stage II or III multiple myeloma and have relapsed after at least one&#xD;
             prior therapies confirmed by the presence of:&#xD;
&#xD;
               1. A new lytic lesion&#xD;
&#xD;
               2. A 25% increase in urine or serum monoclonal protein&#xD;
&#xD;
          -  Patient can have received PS-341 (Velcade) previously and does not require a previous&#xD;
             response.&#xD;
&#xD;
          -  Patients must have measurable disease. One or more of the following must be present to&#xD;
             qualify for this study:&#xD;
&#xD;
               1. Serum M-component greater than or equal to 1.0 gm/dl (10.0 g/L) by serum protein&#xD;
                  electrophoresis&#xD;
&#xD;
               2. Urine M-protein excretion &gt; 200 mg/24 (0.2 g/24h) hours, by urine protein&#xD;
                  electrophoresis&#xD;
&#xD;
               3. Abnormal serum free light chain ratio with elevated Kappa or Lambda light chains&#xD;
                  in serum&#xD;
&#xD;
          -  Baseline measurements must be done within 21 days of study entry.&#xD;
&#xD;
          -  Karnofsky Performance Status Scale &gt; 60.&#xD;
&#xD;
          -  Greater than or equal to 18 years of age.&#xD;
&#xD;
          -  Expected survival of greater than 8 weeks.&#xD;
&#xD;
          -  Swallow intact study medication tablets.&#xD;
&#xD;
          -  Can follow directions or has a caregiver who will be responsible for administering&#xD;
             study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously treated with R115777 (Zarnestra).&#xD;
&#xD;
          -  Undergone an allogeneic bone marrow transplant.&#xD;
&#xD;
          -  A platelet count of &lt;100,000 x 10 to the 9 power/L within 14 days before enrollment.&#xD;
&#xD;
          -  Absolute neutrophil count of &lt;1.0 x 10 to the 9 power/L within 14 days before&#xD;
             enrollment.&#xD;
&#xD;
          -  Measured creatinine &gt; 1.5 X the upper limits of normal within 14 days before&#xD;
             enrollment.&#xD;
&#xD;
          -  Greater than or equal to Grade 2 peripheral neuropathy within 14 days before&#xD;
             enrollment.&#xD;
&#xD;
          -  Hypersensitivity to bortezomib, boron, mannitol or imidazole compounds&#xD;
&#xD;
          -  Female subject is pregnant or breast-feeding. Confirmation that the subject is not&#xD;
             pregnant must be established by a negative serum beta-human chorionic gonadotropin&#xD;
             (beta-hCG) pregnancy test result obtained during screening.&#xD;
&#xD;
          -  Received other investigational drugs within 14 days of enrollment or immunotherapy&#xD;
             within 30 days of enrollment.&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  Ongoing radiation therapy or radiation therapy within 14 days prior to first&#xD;
             treatment.&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 30 days prior to first treatment.&#xD;
&#xD;
          -  Therapy with high-dose corticosteroids within 14 days prior to first treatment.&#xD;
&#xD;
          -  Presence of any of the following excludes a patient from entering the study until such&#xD;
             condition is resolved (determined within 14 days prior to the first treatment):&#xD;
&#xD;
               1. Elevated total bilirubin &gt; 2mg/dl, or direct bilirubin &gt; 2 times the ULN.&#xD;
&#xD;
               2. Serum glutamic oxaloacetic transaminase (AST, formerly SGOT) or serum glutamic&#xD;
                  pyruvic transaminase (ALT, formerly SGPT) &gt; 2 times the ULN&#xD;
&#xD;
               3. Serum calcium &gt; 12 mg/dL.&#xD;
&#xD;
               4. Concurrent serious infection.&#xD;
&#xD;
               5. Life-threatening illness (unrelated to tumor).&#xD;
&#xD;
          -  History of any other ACTIVE and INVASIVE cancer other than the present condition&#xD;
             (except non-melanoma skin cancer), unless in complete remission and off of all therapy&#xD;
             for that disease for a minimum of 3 years.&#xD;
&#xD;
          -  Prohibited/allowable medications or precautions:&#xD;
&#xD;
               1. Enzyme-inducing anti-epileptic medications (e.g. phenytoin, phenobarbital,&#xD;
                  carbamazepine) are not allowed.&#xD;
&#xD;
               2. Non-enzyme anti-epileptic medications will be allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Alsina, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <name_title>Melissa Alsina</name_title>
    <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
  </responsible_party>
  <keyword>Velcade (PS-341)</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Zarnestra (R115777)</keyword>
  <keyword>Tipifarnib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

